Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Massachusetts special commission on Xylazine convenes to study contaminated drug supply; report deadline moved to March 30, 2026
Summary
Legislative co-chairs opened the first public meeting of the Special Commission on Xylazine to study public-health risks from the drug's presence in the unregulated supply. The commission’s statutory charge, planned hearings and a staff‑driven schedule were presented; the final report deadline was extended to March 30, 2026.
The Special Commission on Xylazine, convened by the Joint Committee on Mental Health, Substance Use and Recovery, held its first public meeting remotely, with House chair Mindy Dom and Senate co‑chair Sen. John Vilas presiding.
The commission is charged to “study and make recommendations on ways to address the public health and safety concerns posed by the proliferation of Xylazine as an additive to illicit drugs, including, but not limited to, fentanyl,” Dom said. The commission will examine three core areas listed in its charge: best practices to regulate and oversee Xylazine…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
